A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing

Inclusion Criteria: * Japanese patients, age 20 to 80 years inclusive, requiring colonoscopy * Female patients should be post-menopausal (women ≥45 years with no menstrual period for at least 12 months without an alternative medical cause), or be surgically sterile, or be using medically approved contraception, throughout the trial period. * Fertile female patients must have a confirmed negative pregnancy test at screening and randomization * Patients must have had more than or equal to 3 spontaneous bowel movements per week prior to the colonoscopy * Written informed consent obtained prior to any study-related procedure Exclusion Criteria: * Acute surgical abdominal conditions, such as acute intestinal obstruction or intestinal perforation, diverticulitis, appendicitis. If intestinal obstruction and perforation are suspected, perform appropriate diagnostic studies to rule out these conditions * Active (acute/exacerbation of/severe/uncontrolled) Inflammatory Bowel Disease (IBD) * Any prior colorectal surgery, excluding appendectomy, haemorrhoid surgery or prior endoscopic procedures * Colon disease (history of colonic cancer, toxic megacolon, idiopathic pseudo-obstruction, hypomotility syndrome) * Gastrointestinal disorder (active ulcer, outlet obstruction, retention, gastroparesis, ileus) * Ascites. * Upper gastrointestinal surgery (gastric resection, gastric banding, gastric by-pass) * Uncontrolled angina and/or Myocardial Infarction (MI) within last 3 months, Congestive Heart Failure (CHF), or uncontrolled hypertension * Renal insufficiency (any of the serum creatinine, or serum potassium value exceeding the upper limits of the normal range at screening) or a history of this event * Participation in any other clinical trial during the past 3 months * Any clinically significant laboratory value at screening, including pre-existing electrolyte abnormality, based on clinical history that the investigators feel may affect the study evaluation * Hypersensitivity to active ingredients * Subject who cannot suspend the prohibited medications * Subjects not appropriate to participate in the study as deemed by the investigator